Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer

Androgen receptor (AR) antagonist MDV3100 is the first therapeutic approach in treating castration-resistant prostate cancer (CRPC), but tumours frequently become drug resistant via multiple mechanisms including AR amplification and mutation. Here we identify the small molecule Ailanthone (AIL) as a...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Nat Commun
Main Authors: He, Yundong, Peng, Shihong, Wang, Jinhua, Chen, Huang, Cong, Xiaonan, Chen, Ang, Hu, Meichun, Qin, Min, Wu, Haigang, Gao, Shuman, Wang, Liguo, Wang, Xin, Yi, Zhengfang, Liu, Mingyao
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2016
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5159881/
https://ncbi.nlm.nih.gov/pubmed/27959342
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms13122
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares